Drugs / Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)
Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07611513 | May 2026 → Dec 2027 expected | hand, foot and mouth disease, herpangina | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07611513 ↗ |
| Modality | Vaccine | “Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)” NCT07611513 ↗ |
| Route | Intramuscular | “Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months” NCT07611513 ↗ |